Concern over contraceptive solutions for women at high risk of HIV

Organisation: Position: Deadline Date: Location:

HIV-1Over the past three days, the World Health Organisation guideline development group has been meeting to discuss its recommendations for the use of contraceptive methods by women at high risk of contracting HIV. A Daily Maverick report says that in particular, the group will review the status of the three monthly injectable contraceptive Depo-Provera, using new evidence from a randomised clinical trial, the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.

The ECHO trial was carried out in South Africa, Kenya, Swaziland, and Zambia, and was designed to settle ongoing uncertainty and debate over whether the three monthly injectable contraceptive Depo-Provera, a copper IUD (non-hormonal inter-uterine device) and an LNG implant (a progestin-based implant containing the hormone levonorgestrel) increased the possibility of HIV transmission in women who used it.

The report says the study found no substantial difference in the risk of getting HIV among 7,829 women randomly assigned to use one of three reversible, highly effective contraceptives: DMPA-IM, copper IUD and LNG implant.

But the global leaders in an open letter to WHO argue that the way that the study was designed showed a “lack of concern for high rates of HIV infection and lack of access to safe contraception”.

Daily Maverick report

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.